Continuous Lidocaine Infusion for Management of Perioperative Burn Pain

Phase 4

Completed

Brief Summary: Thermal injury results in one of the most intense and prolonged forms of pain the body can experience. Opioid narcotics are the most powerful drugs for acute and chronic pain, and their use in the perioperative period has been the mainstay of treatment; although medication requirements in burn patients are often underestimated. More medication may not be the answer, as relatively large doses of short acting opioids in the operative theater are associated with greater postoperative opioid consumption and higher pain scores. Furthermore, extensive use of opioids has resulted in the development of by hyperalgesia and allodynia. Lidocaine is an amide local anesthetic that has analgesic, anti-hyperalgesic, antiarrhythmic, and anti-inflammatory properties. Over the past 25 years, systemic lidocaine has been used for perioperative pain management in a variety of surgical procedures. The design of this study will examine if lidocaine will reduce the pain scores and narcotic utilization in patients undergoing surgical procedures for burn injuries. The intervention group will receive a bolus dose of lidocaine followed by a continuous infusion over 24 hours. The control group will get an equal volume of saline. The investigators will compare pain scores, opioid use, and narcotic equivalents based on body weight and burn surface area (BSA) grafted.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Burn patient < 18 years of age
Intubated patient on sedation drip
Prolonged hypotension defined as Systolic Blood Pressure (SBP) < 90 mm/Hg for greater than 30 minutes in the pre-op area
Severe underlying cardiovascular disease (documented ejection fraction < 40%)
Documented conduction block, bradycardia or active congestive heart failure
Documented active gastritis or ulcers
Previous steroid medication history if documented adrenal insufficiency
Patient with documented liver disease
Patient with epilepsy or known seizure disorder
Pregnant Women

Arm && Interventions

Group	Intervention	Description
Normal pain management	Placebo	Normal saline (bolus followed by continuous infusion)
Lidocaine	Lidocaine	Lidocaine (Pre-operative = 1.5kg/mg over a minimum of 30 minutes; peri-operative = 2.0mg/kg/hour; Post-operative = 1.5kg/mg/hour)

Primary Outcome Measures

Name	Time	Method
Narcotic Consumption (Measured in mg/kg Narcotic Consumption)	24-hours post surgery	The infusion was initiated at 1.5mg/kg for 30 minutes prior to surgery start, followed by a 2.0 mg/kg/hr infusion at the time of incision start. The rate was reduced to 1.5mg/kg/hr for the remainder of the 24 hour period. A standardized post-operative pain management strategy (morphine and oxycodone) was followed by clinical staff, based on a standardized pain scale rating tool. The difference in narcotic consumption and number of pain medication doses over the 72-hour post-operative period was compared using an unadjusted Wilcoxon rank sum test due to non-normal data distribution.

Secondary Outcome Measures